Aim Immunotech Stock Price, News & Analysis

AIM ImmunoTech Inc. announced that CEO Thomas K. Equels has been appointed to the Board of Directors of BioFlorida Inc. This organization represents over 6,700 establishments in Florida's life sciences sector, employing nearly 94,000 individuals. Equels expressed pride in contributing to the potential development of therapies for serious diseases, including cancers and COVID-19. This appointment may enhance AIM's influence within Florida's vibrant life sciences industry.

AIM ImmunoTech has announced a Phase 2a Human Challenge Trial to evaluate Ampligen as an intranasal antiviral therapy against human rhinovirus and influenza. Sponsored by hVIVO, this trial aims to assess Ampligen's effectiveness, with a focus on its potential to serve as a prophylaxis against future respiratory viruses, including SARS-CoV-2. Following the completion of a successful Phase 1 study, which reported no severe adverse events in 40 subjects, the Phase 2a trial is expected to begin in Q4 2021, potentially accelerating the drug's development process.

On July 6, 2021, AIM ImmunoTech Inc. (NYSE American: AIM) announced an upcoming investor update webcast scheduled for July 14, 2021, at 11:00 a.m. Eastern Time. The session will cover recent achievements and future milestones. Investors are encouraged to submit their questions via email before the call. The webcast can be accessed through the company’s website, and a replay will be available until July 14, 2022. AIM ImmunoTech is focused on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19.

AIM ImmunoTech Inc. has announced the completion of treatment in its Phase 1 clinical study of Ampligen as a potential intranasal therapy for respiratory viruses. A total of 40 healthy subjects participated, with no Severe Adverse Events reported. With positive results, the company is now planning a Phase 2 study to evaluate Ampligen's efficacy as a broad-spectrum respiratory virus prophylaxis, targeting various viruses including influenza and coronaviruses. This development aims to provide preventive therapy for vulnerable populations, pending further testing.

AIM ImmunoTech Inc. has received a patent in the Netherlands for Ampligen, recognizing its potential as a combination therapy with checkpoint blockade inhibitors. The drug's efficacy in treating cancer patients infected with SARS-CoV-2 has been highlighted in a peer-reviewed study. Research suggests Ampligen may activate immune responses against cancers and reduce COVID-19 severity. The patent, effective until December 2039, marks significant progress in AIM's drug development efforts.

AIM ImmunoTech Inc. has announced a two-year extension of its Material Transfer and Research Agreement with Shenzhen Smoore Technology Limited to develop Ampligen as a potential inhalation therapy for COVID-19 and other respiratory diseases. Preliminary testing showed that Ampligen could reduce SARS-CoV-2 infectious viral yields by 90% at achievable dosages. AIM plans to begin a Phase 1/2 clinical study alongside the development of Smoore's inhalation device, focusing on safety and efficacy before year-end.

AIM ImmunoTech Inc. announced the completion of dosing for Cohort 3 in a Phase 1 clinical study investigating Ampligen as an intranasal therapy. The study, conducted by the Centre for Human Drug Research, involved 40 healthy subjects and reported no serious adverse events. Cohorts received escalating doses up to 500 μg, with Cohort 4 now receiving 1250 μg. The study aims to evaluate Ampligen’s safety and biological activity as a potential treatment for COVID-19 and other viral diseases. Future updates depend on ongoing trial results and regulatory approvals.

AIM ImmunoTech Inc. (NYSE American: AIM) reported its financial results for Q1 2021, highlighting a cash position of $63.6 million, up from $54.4 million at year-end 2020. Research and development expenses increased to $1.4 million from $0.9 million year-over-year, while general and administrative expenses decreased slightly to $2.1 million. The net loss improved to $3.6 million or $0.08 per share, compared to $3.8 million or $0.22 per share last year. CEO Thomas K. Equels emphasized advancements in clinical programs targeting cancer and viral diseases, including COVID-19.

AIM ImmunoTech Inc. (NYSE American: AIM) announced that CEO Thomas K. Equels participated in a 'Fireside Chat' video interview with Ed Woo from Ascendiant Capital Markets on May 3, 2021. The discussion highlighted AIM's recent accomplishments and key upcoming goals, as well as the financial and operational outlook for the company. AIM ImmunoTech focuses on developing therapeutics for multiple cancers, immune disorders, and viral diseases, including COVID-19. A link to the interview is available on AIM's website.